Erin Sarzynski, MD
Internal Medicine · Okemos, MINPI 1669676680
Payments from drug & device makers
Across 82 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$271
- AbbVie$220
- Novo Nordisk$200
- Boehringer Ingelheim$170
- AstraZeneca$97
- Otsuka America Pharmaceutical, Inc.$69
- plus $483 from 16 others
What the payments were for
- Food & beverage$1,510100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 15 | $271 |
| AbbVie | 12 | $220 |
| Novo Nordisk | 11 | $200 |
| Boehringer Ingelheim | 8 | $170 |
| AstraZeneca | 7 | $97 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Lilly USA, LLC | 4 | $68 |
| Bayer | 3 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $58 |
| Abbott | 3 | $49 |
| Novartis | 1 | $34 |
| Amgen | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Averitas Pharma Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Biogen | 1 | $18 |
| Phadia US Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| GSK | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Coloplast | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$1,510 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 13 | $8,986 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $715 |
| Atorvastatin Calcium | 45 | $460 |
| Rosuvastatin Calcium | 20 | $424 |
| Losartan Potassium | 31 | $292 |
| Levothyroxine Sodium | 36 | $288 |
| Gabapentin | 11 | $267 |
| Metoprolol Succinate | 17 | $208 |
| Celecoxib | 12 | $182 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $175 |
| Amlodipine Besylate | 18 | $150 |
| Lisinopril | 32 | $140 |
| Montelukast Sodium | 13 | $120 |
| Metformin Hcl | 18 | $115 |
| Tamsulosin Hcl | 13 | $103 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Okemos
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.